Strides Pharma Science Ltd

Event details

• USFDA completed cGMP inspection of Bengaluru flagship facility from May 12–20, 2026.
• Five Form 483 observations were issued; company submitted a comprehensive response within the timeline.
• USFDA classified the inspection as Voluntary Action Indicated (VAI) and issued the Establishment Inspection Report.
• Facility manufactures tablets, capsules and oral liquids across diverse product portfolio.
• Inspection timeline May 12–20, 2026; prior Form 483 disclosed May 20, 2026.

AGM details

• Date/time: 14 Aug 2026 at 12:15 IST; mode: Video Conferencing.
• Voting rights cut-off: 7 Aug 2026.
• Notice dispatched: 21 Jul 2026.

Key resolutions

• Ordinary – Adoption of Audited Financial Statements (incl. consolidated) for year ended 31 Mar 2026; passed.
• Ordinary – Declaration of Final Dividend for year ended 31 Mar 2026; passed.
• Ordinary – Re-appointment of retiring director Arun Kumar as Non-Executive Director; passed.
• Special – Payment of Commission to Non-Executive Directors in event of profit inadequacy; passed.
• Ordinary – Appointment of Aditya Arun Kumar as Non-Executive Director; passed.
• Special – Appointment of Venkata Seetharama Raju Pakalapati as Executive Director; passed.

Voting results

• Res 1: Passed; near-unanimous support with negligible opposition.
• Res 2: Passed; minimal dissent.
• Res 3: Passed; small minority opposed.
• Res 4: Passed; majority support with some abstentions.
• Res 5: Passed; limited opposition.
• Res 6: Passed; strong overall support.

Dividend

• Final dividend approved for FY ended 31 Mar 2026.

Director changes

• Arun Kumar re-appointed as Non-Executive Director.
• Aditya Arun Kumar appointed as Non-Executive Director.
• Venkata Seetharama Raju Pakalapati appointed as Executive Director.

Auditors

• No changes to statutory/secretarial/cost auditors disclosed.

Related party transactions

• No material related party transactions approved; promoter group not interested.

Other material approvals

• No additional material approvals disclosed.

AGM details

• AGM held on 14 August 2026 from 12:15 to 13:34 IST via video conference.

Key resolutions

• Ordinary: receive and adopt Audited Financial Statements for year ended 31 March 2026.
• Ordinary: declare final dividend for the year ended 31 March 2026.
• Ordinary: re-appoint Arun Kumar, retiring director.
• Special: payment of commission to non-executive directors in case of profit inadequacy.
• Ordinary: appoint Aditya Arun Kumar as non-executive director.
• Special: appoint Venkata Seetharama Raju Pakalapati as executive director.

Voting status

• Voting results to be declared within two working days, by 18 August 2026.

Directors

• Aditya Arun Kumar appointed non-executive director.
• Arun Kumar re-appointed as director (retiring director).

Auditors

• Statutory and internal auditors attended; no change announced at AGM.

Business Overview

• Strides is a global generic medicines company with US Generics and Ex-US Markets segments.
• Pivot Path stake divestment unlocked ₹1,000m value; OneSource stake valued at ₹3,100m (not debt).

Key Operational Highlights

• Q1 FY27 revenue ₹12,654m, up 13% YoY.
• Ex-US Markets grew 17% YoY.
• US revenue ₹6,282m; launched 2 products; 72 commercialized products.
• Net debt reduced ₹119m; net debt/EBITDA 1.52x; cashflow from operations ₹1,087m.
• Pivot Path divestment unlocked ₹1,000m value; EcoVadis score 68/100.
• ANDAs filed 228; approved 210 (152 products) as of Jun'26.
• FY26 update: Ex-US expansion across UK, Nordics, Africa; new filings.

Financial Performance

• Revenue ₹12,654m; YoY +13%.
• Gross margin 60.9%; YoY +60 bps.
• EBITDA ₹2,298m; margin 18.2%; YoY +5.4%.
• PAT ₹1,655m; YoY +56.7%; Reported EPS ₹17.0; Operational EPS ₹13.4.
• Net debt ₹14,246m; Net debt/EBITDA 1.52x.
• Tax on Pivot Path ₹208m included.
• Q1FY27 operating cashflow ₹1,087m.

Capital Structure & Liquidity

• Credit rating upgrade: CARE A+; Stable.
• Gross debt ₹17,086m; cash ₹2,840m; net debt ₹14,246m.
• Net debt/EBITDA 1.52x.
• Pivot Path divestment unlocked ₹1,000m value; OneSource investment ₹3,100m not included in net debt.

Strategic Outlook

• Focus on operating cashflow and debt reduction; strengthen Net Debt/EBITDA.
• Invest in R&D and capex for long-term growth.
• Ex-US growth remains key driver; US launches expected H2FY27.
• File and launch more ANDAs, including nasal sprays and controlled substances.

Risks & Mitigation

• Geopolitical disruptions raised freight costs by ~₹131m; cost optimization ongoing.
• Regulatory delays and longer timelines in new territories; diversification across Ex-US markets.

Governance & Leadership

• MD & Group CEO: Badree Komandur; Group CFO: Vikesh Kumar.
• No governance changes disclosed.

Consolidated results

• Revenue from operations: Rs 12,654.07 mn for quarter ended June 30, 2026.
• Total income: Rs 12,702.97 mn; QoQ down from Rs 13,315.98 mn.
• Profit before tax: Rs 1,996.16 mn (consolidated after associates).
• Tax expense: Rs 341.23 mn; Profit after tax: Rs 1,654.93 mn.
• EPS (basic/diluted): Rs 17.02 for the quarter.
• Exceptional item: Rs 631.97 mn gain in consolidated results.
• Auditor status: Limited review with unmodified opinion (BSR & Co LLP).
• Final dividend: Rs 5 per share; cash outflow ~ Rs 461 mn; subject to AGM.

Standalone results

• Revenue from operations: Rs 5,826.48 mn; total income Rs 5,841.23 mn.
• Profit before tax: Rs 847.58 mn; profit after tax: Rs 729.28 mn.
• EPS (basic/diluted): Rs 7.91.
• Standalone results unaudited; March 31, 2026 figures audited.

Corporate actions & notes

• Demerger of Arco Lab into Pivot Path; effective June 1, 2026.
• Pivot Path stake diluted to 19.95%; net gain Rs 764.01 mn; Master Services Agreement.
• Group ceased to have control; retained interest fair-valued as associate.
• Recall provisions for ranitidine/azide issues: Rs 14.32 mn (Jun), Rs 9.59 mn (Mar).
• Additional recall provisions: Rs 54.17 mn; legal fees recorded as exceptional items.
• Final dividend Rs 5 per share; subject to AGM approval.

Dividend entitlement details

• Final dividend of ₹5 per equity share (₹10 face value) for FY2025-26, subject to shareholder approval.
• Record date fixed at 31 July 2026 to determine dividend entitlement.
• Payable within 30 days from declaration to registered bank accounts, subject to TDS.

Dematerialisation/rematerialisation processing

• Details of dematerialised/rematerialised securities for the period have been furnished to all stock exchanges.

Nature of Restructuring

• Sale of Strides' majority stake in Pivot Path to a consortium led by Ascent Capital and Vintage Classic.

Entities Involved

• Strides Pharma Science Limited sold Pivot Path.
• Pivot Path ceased to be a wholly-owned subsidiary; now an Associate.
• Buyer consortium led by Ascent Capital; co-investor Vintage Classic.

Transaction Details

• Aggregate consideration ₹1,000 million; ₹750 million received; ₹250 million payable on first anniversary.
• Completion: Pivot Path ceased to be subsidiary effective July 1, 2026.

Financial Impact

• Pivot Path moved from subsidiary to associate; no disclosed turnover or net worth figures.

Rationale & Strategy

• Strategic objective to unlock value by monetizing Pivot Path via external consortium.

Related Party & Shareholding

• External investor group; not a related party; no change in Strides' shareholding.

Approvals & Timeline

• Remaining ₹250 million payable on first anniversary; July 1, 2027.